Bristol trumpets Opdivo quality-of-life data ahead of Keytruda head and neck cancer showdown


COPENHAGEN, Denmark--Regulatory authorities are already evaluating Bristol-Myers Squibb’s Opdivo in head and neck cancer, based on impressive survival rates posted in a Phase III study. In the meantime, though, Bristol has gone back through through that study data to show its med topped the standards of care in quality-of-life metrics, too.

In the CheckMate-141 study, second-line patients with recurrent or metastatic squamous cell carcinoma of the head and neck reported stabilized symptoms and functioning--including physical and social functioning--during the first 15 weeks of Opdivo treatment, Bristol said Sunday at the ESMO 2016 Congress.

On the flip side, those study participants taking methotrexate, docetaxel or Eli Lilly’s Erbitux saw their quality of life significantly worsen over the same time period.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Opdivo also significantly delayed the worsening of symptoms such as fatigue and insomnia when compared with that trio of treatments.

The data are important, considering the “debilitating physiological effects” that often pile onto the “emotional and social challenges brought on by the condition despite current treatment options,” Kevin Harrington, a professor at the Institute of Cancer Research in London, said in a statement.

And they could also prove useful considering the edge Bristol’s rival, Merck, already has in head and neck cancer with Opdivo archrival Keytruda. That med won the FDA’s green light in August after achieving a 16% response rate in Merck’s Keynote-012 study; 82% of those patients were still responding to the therapy at the 6-month mark.

But BMS may not be that far behind. Regulators are currently weighing its application for a head-and-neck nod, which includes data showing that Opdivo exended the median survival rate of patients to 7.5 months from 5.1 months for the three standards of care. 36% of patients in the study’s Opdivo arm also lived for at least 12 months, results showed.

Related Articles:
Merck's Keytruda wins a double-header with new FDA approval in head-and-neck cancer
Opdivo gives head and neck cancer patients a shot at 12-month survival
Keytruda, Opdivo near new cancer uses where they won't butt heads--at least at first

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.